Trends in and Predictors of Patient Pharmacogenomic Test Uptake in a National Healthcare System.

Autor:	Silva A; Center of Innovation for Complex Chronic Healthcare, Edward Hines Jr. Veterans Affairs Hospital, Hines, IL 60141, USA; Parkinson School of Health Sciences and Public Health, Loyola University Chicago, Maywood, IL 60153, USA. Electronic address: Asilva8@luc.edu., Voora D; VA National Pharmacogenomics Program, Department of Veteran's Affairs, Durham, NC 27705, USA; Department of Medicine, Duke Precision Medicine Program, Duke University School of Medicine, Durham, NC 27599, USA., Wu RR; Department of Medicine, Duke Precision Medicine Program, Duke University School of Medicine, Durham, NC 27599, USA; 23AndMe, Sunnyvale, CA, USA., Bartle B; Center of Innovation for Complex Chronic Healthcare, Edward Hines Jr. Veterans Affairs Hospital, Hines, IL 60141, USA., Chanfreau-Coffinier C; VA Informatics & Computing Infrastructure (VINCI), Salt Lake City VA Health Care System, Salt Lake City, UT 84148, USA., Hung A; Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA., Voils CI; Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA; William S. Middleton Memorial Veterans Hospital, Madison, WI 53705, USA.
Jazyk:	angličtina
Zdroj:	Genetics in medicine : official journal of the American College of Medical Genetics [Genet Med] 2024 Oct 28, pp. 101308. Date of Electronic Publication: 2024 Oct 28.
DOI:	10.1016/j.gim.2024.101308
Abstrakt:	Purpose: Better understanding patient uptake of pharmacogenomic (PGx) testing may inform its implementation and maximize the benefits that such testing can confer. This study examined patient and provider factors associated with PGx test ordering in a national healthcare system where panel-based testing was implemented as part of routine care. Methods: We used a retrospective matched cohort design and data from the Veterans Health Administration Corporate Data Warehouse. A conditional logistic model was used to identify factors associated with a PGx order receipt and estimate odds ratios and 95% confidence intervals. Results: The following patient factors predicted receipt of a PGx test order: younger age, married status, rural residence, non-Hispanic Black or Hispanic race/ethnicity, PGx educational mailer receipt, depression diagnosis, allergy to a drug on the panel, prescriptions for drugs on the panel, and specialty care visits (p<0.05). Additionally, patients whose providers were female, younger, a nurse practitioner/physician assistant or pharmacist, or participated in an educational mailer program were more likely to receive an order (p<0.05). Conclusion: This study highlights factors that may facilitate or hinder the widespread and equitable implementation of PGx testing in a large national healthcare system. The information is being used to further refine the program. (Copyright © 2024. Published by Elsevier Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu